Partnership Seeks to Accelerate Development of Innovative Therapies
Approval marks first oral therapy for MCL patients, and a new option for patients with unmet medical need
Anti-CD20-Interferon Alpha Fusion Protein is a promising therapy for NHL patients resistant to standard therapy
If you're a member of the media, you can direct all inquiries for The Leukemia & Lymphoma Society's (LLS's) Illinois Chapter to: Jessica Hatcher, Manager, Marketing & Communications at email@example.com or 312-568-7739.
Check back for a selection of recent news clips about LLS campaigns, participants and impact.